Pricing Log in Create free account

LB Pharmaceuticals Inc (LBRX) vs Nektar Therapeutics (NKTR)

LB Pharmaceuticals Inc and Nektar Therapeutics are both Biotechnology companies. LB Pharmaceuticals Inc and Nektar Therapeutics are of similar size ($1.2B and $1.2B). LB Pharmaceuticals Inc has the higher net margin (0.00% vs −287.8%) and the lower return on invested capital (−1,304.8% vs −40.2%). Across the 12 metrics below, LB Pharmaceuticals Inc leads on 7 and Nektar Therapeutics on 5.

Valuation

Metric LBRX NKTR Biotechnology median
P/E n/m n/m 10.60
P/S n/m 22.56 9.40
P/B 3.81 1.36 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 19.22 9.02
Earnings yield (8.19%) (17.99%) (32.88%)
Free cash flow yield (6.54%) (19.01%) (23.13%)

Profitability

Metric LBRX NKTR Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% (257.80%) 0.00%
Net margin 0.00% (287.84%) 0.00%
Free cash flow margin 0.00% (428.72%) 0.00%
Return on equity (72.07%) (35.75%) (51.96%)
Return on assets (47.38%) (24.12%) (46.06%)
Return on invested capital (1,304.79%) (40.20%) 0.00%

Growth

Metric LBRX NKTR Biotechnology median
Revenue growth (TTM) — (27.15%) 6.76%
EPS growth (last fiscal year) 98.22% (11.89%) 29.88%
Revenue growth, 5-year CAGR — (18.43%) 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric LBRX NKTR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 15.08 10.42 4.97
Net debt to EBITDA 9.90 1.77 1.01

Dividend

Metric LBRX NKTR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LBRX NKTR Biotechnology median
Market cap 1.23b 1.23b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack